<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01767922</url>
  </required_header>
  <id_info>
    <org_study_id>SE-ISO-2007-01</org_study_id>
    <nct_id>NCT01767922</nct_id>
  </id_info>
  <brief_title>Multicentre, Double-blind Study Versus Placebo on Impact and Safety of Extramel® 140 IU on Perceived Stress, Physical and Intellectual Fatigue, Pain Perception if Present, and the Impact on the Quality of Life</brief_title>
  <acronym>Ex Stress II</acronym>
  <official_title>Multicentre, Double-blind Study Versus Placebo on the Impact and Safety of the Daily Administration of Extramel® 140 IU for 12 Weeks on Perceived Stress, Physical and Intellectual Fatigue, Pain Perception, if Present, and the Impact on the Quality of Life of 70 Subjects Included, of Which 60 That Can be Evaluated</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bionov</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SEPPIC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bionov</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives of this Multicentre, double-blind study versus placebo were to evaluate impact and
      safety of the daily administration of Extramel® 140 IU SOD for 12 weeks on perceived stress,
      physical and intellectual fatigue, pain perception, if present, and the impact on the quality
      of life of 70 subjects included with 60 that can be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perceived Stress : Change from base line in Cohen PSS 14 scale at V2 and V3</measure>
    <time_frame>Evaluation performed at inclusion day (V1), after 4 weeks at D28 (V2) and then at the end of study visit on D84 (V3).</time_frame>
    <description>Evaluation performed by Cohen PSS 14 scale. It should be noted that in order to be included the patient had to present a minimum score of 30 on the Cohen scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of evolution of Physical fatigue</measure>
    <time_frame>Evaluation performed at inclusion day (V1), after 4 weeks at D28 (V2) and then at the end of study visit on D84 (V3).</time_frame>
    <description>Evaluation performed by Prevost subjective fatigue scale and Ruffier test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of evolution of Intellectual fatigue</measure>
    <time_frame>Evaluation performed at inclusion day (V1), after 4 weeks at D28 (V2) and then at the end of study visit on D84 (V3).</time_frame>
    <description>Evaluation performed by Stroop test, Reverse Stroop test and 15-words Rey test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of evolution of pain</measure>
    <time_frame>Evaluation performed at inclusion day (V1), after 4 weeks at D28 (V2) and then at the end of study visit on D84 (V3).</time_frame>
    <description>Evaluation of subjects' perceived chronic pain (if existing), was performed using a simple visual analog scale (VAS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of evolution of subject Quality of life</measure>
    <time_frame>Evaluation performed at inclusion day (V1), after 4 weeks at D28 (V2) and then at the end of study visit on D84 (V3).</time_frame>
    <description>Evaluation of subjects' quality of life, was performed by using Quality of Life SF36 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of evolution of subject Quality of life</measure>
    <time_frame>Evaluation performed at inclusion day (V1), after 4 weeks at D28 (V2) and then at the end of study visit on D84 (V3).</time_frame>
    <description>Evaluation of subjects' quality of life, was performed by using Hamilton anxiety scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of evolution of subject Quality of life</measure>
    <time_frame>Evaluation performed at inclusion day (V1), after 4 weeks at D28 (V2) and then at the end of study visit on D84 (V3).</time_frame>
    <description>Evaluation of subjects' quality of life, was performed by using Personnal stress profile questionnary.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluation of safety</measure>
    <time_frame>Global safty evaluation performed at the end of study.</time_frame>
    <description>Assessment of the safety performed by analysis of adverse events that occurred throughout the study.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Life Stress</condition>
  <condition>Fatigue</condition>
  <condition>Pain</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Extramel 10 mg - 140 UI SOD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm receives daily one capsule Extramel 10 mg containing 140 UI of SOD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - exipients only</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm receives daily one capsule Placebo containing excipients only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Extramel 10 mg - 140 UI SOD</intervention_name>
    <description>Subjects took one capsule of Extramel® 140 IU, or its corresponding placebo, daily over 12 weeks.
Each volunteer was seen for the 3 visits:
visit V1, so-called inclusion visit (D0),
visit V2 at 28 days, tolerance of +/- 3 days, (D28) and
visit V3 at 84 days, tolerance of +/- 3 days, (D84).</description>
    <arm_group_label>Extramel 10 mg - 140 UI SOD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo - Excipient only</intervention_name>
    <arm_group_label>Placebo - exipients only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female person using an effective contraceptive method, with a negative urine
             pregnancy test on the inclusion visit for the women of reproductive age.

          -  Older than 30 years and younger than 65 years

          -  BMI ≤ 30

          -  Score greater than 30 on the Cohen perceived stress scale PSS 14.

          -  Score between 5 and 20 in the Hamilton anxiety scale (excluding the limits).

          -  Presenting an impact of stress on at least one of the following domains.

               -  pain domain with a score greater than 20 millimeters measured on the visual pain
                  evaluation scale,

               -  physical condition domain with a score greater than 50 on the Prevost subjective
                  fatigue scale,

               -  the psychical condition domain with a global score below 160 in the Stroop test
                  and the reverse Stroop test.

          -  Stable professional activity since at least 1 year.

          -  Completely healthy on the day of inclusion, and not taking any medicinal product or
             dietary supplement with an anti-stress or anti-pain objective.

          -  Not taking any herbal tea or drink with an anti-stress or anti-pain objective.

          -  Accepting not to modify his/her dietary habits.

          -  Having given his/her free, informed and express consent.

          -  Capable of understanding the nature of the objectives, the consequences of the study
             and accepting to comply with the protocol requirements.

          -  Affiliated with a social security insurance or beneficiary of such an insurance
             system.

        Exclusion Criteria:

          -  Subject presenting an acute pain or pain considered to be incapacitating by the
             patient him/herself or the observer physician.

          -  Subject currently under a chronic or acute treatment indicated for stress or anxiety,
             irrespective of the treatment.

          -  Subject currently under a chronic or acute treatment indicated for pain problems,
             irrespective of the treatment.

          -  Pregnant and/or breast-feeding women.

          -  Any person who does not satisfy by definition the inclusion criteria.

          -  Adult protected by the law.

          -  Any history of psychiatric disease.

          -  Any pathology in progress or active in the previous month.

          -  Any administration of a dietary supplement in progress or in the previous month.

          -  Any subject who within the 3 months following inclusion is likely to experience a
             major modification of his/her life rhythm (For example marriage, birth of a child,
             scheduled hospitalization, important exam, etc.) this is left to the discretion of the
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry CANTIN, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Patrick LEPRINCE, MD</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Hubert TAUPE, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>ISOCLIN</affiliation>
  </overall_official>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2013</study_first_submitted>
  <study_first_submitted_qc>January 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2013</study_first_posted>
  <last_update_submitted>January 17, 2013</last_update_submitted>
  <last_update_submitted_qc>January 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Super-Oxyd-Dismutase</keyword>
  <keyword>SOD</keyword>
  <keyword>melon juce</keyword>
  <keyword>perceived stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Stress, Psychological</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

